188 EAST BLAINE ST., SUITE 200, SEATTLE, WA
News, Articles of Incorporation, Bylaws
Reports First Quarter 2024 Financial Results
Enters Into Agreement to Acquire Alpine Immune Sciences
Changes in Board, Management or Compensation
Provides Corporate Update and Full Year 2023 Financial Results
Material disclosure
News, Material Contracts
Announces Amendment of Acazicolcept Option and License Agreement
Q1
FY 2023 amended
FY 2023
Q3
Q2
FY 2022
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS